JP2008540453A - 播種性カンジダ症および他の感染性因子に対してワクチン接種するための薬学的組成物および方法 - Google Patents
播種性カンジダ症および他の感染性因子に対してワクチン接種するための薬学的組成物および方法 Download PDFInfo
- Publication number
- JP2008540453A JP2008540453A JP2008510281A JP2008510281A JP2008540453A JP 2008540453 A JP2008540453 A JP 2008540453A JP 2008510281 A JP2008510281 A JP 2008510281A JP 2008510281 A JP2008510281 A JP 2008510281A JP 2008540453 A JP2008540453 A JP 2008540453A
- Authority
- JP
- Japan
- Prior art keywords
- candida
- als
- mice
- albicans
- als1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 78
- 201000003984 candidiasis Diseases 0.000 title claims abstract description 69
- 206010042938 Systemic candida Diseases 0.000 title claims abstract description 54
- 208000019164 disseminated candidiasis Diseases 0.000 title claims abstract description 53
- 238000002255 vaccination Methods 0.000 title description 21
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- 239000012678 infectious agent Substances 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 249
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 226
- 229960005486 vaccine Drugs 0.000 claims abstract description 132
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims abstract description 75
- 239000012634 fragment Substances 0.000 claims abstract description 59
- 239000002671 adjuvant Substances 0.000 claims abstract description 58
- 230000002163 immunogen Effects 0.000 claims abstract description 37
- 230000000694 effects Effects 0.000 claims abstract description 35
- 230000027455 binding Effects 0.000 claims abstract description 30
- 230000021164 cell adhesion Effects 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 68
- 210000002889 endothelial cell Anatomy 0.000 claims description 59
- 241000222122 Candida albicans Species 0.000 claims description 43
- 229940095731 candida albicans Drugs 0.000 claims description 26
- 210000002919 epithelial cell Anatomy 0.000 claims description 17
- 230000003053 immunization Effects 0.000 claims description 15
- 238000002649 immunization Methods 0.000 claims description 15
- 102000016359 Fibronectins Human genes 0.000 claims description 14
- 108010067306 Fibronectins Proteins 0.000 claims description 14
- 108010010803 Gelatin Proteins 0.000 claims description 14
- 239000008273 gelatin Substances 0.000 claims description 14
- 229920000159 gelatin Polymers 0.000 claims description 14
- 235000019322 gelatine Nutrition 0.000 claims description 14
- 235000011852 gelatine desserts Nutrition 0.000 claims description 14
- 230000009545 invasion Effects 0.000 claims description 12
- 210000004897 n-terminal region Anatomy 0.000 claims description 9
- 241000222178 Candida tropicalis Species 0.000 claims description 8
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 8
- 241000222126 [Candida] glabrata Species 0.000 claims description 8
- 208000032343 candida glabrata infection Diseases 0.000 claims description 8
- 108010085895 Laminin Proteins 0.000 claims description 7
- 241000222173 Candida parapsilosis Species 0.000 claims description 6
- 229940055022 candida parapsilosis Drugs 0.000 claims description 6
- 230000003511 endothelial effect Effects 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims description 4
- 241000235645 Pichia kudriavzevii Species 0.000 claims 1
- 208000013210 hematogenous Diseases 0.000 abstract description 22
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 201
- 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 88
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 85
- 208000015181 infectious disease Diseases 0.000 description 68
- 230000004083 survival effect Effects 0.000 description 63
- 230000014509 gene expression Effects 0.000 description 47
- 239000000758 substrate Substances 0.000 description 40
- 206010016654 Fibrosis Diseases 0.000 description 39
- 230000004761 fibrosis Effects 0.000 description 39
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 101150100117 gfm1 gene Proteins 0.000 description 34
- 101150016954 efg1 gene Proteins 0.000 description 32
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 30
- 230000002950 deficient Effects 0.000 description 29
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 28
- 230000002538 fungal effect Effects 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 101150001232 ALS gene Proteins 0.000 description 18
- 238000000585 Mann–Whitney U test Methods 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 18
- 206010030113 Oedema Diseases 0.000 description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 17
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 17
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 230000037361 pathway Effects 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 16
- 206010007134 Candida infections Diseases 0.000 description 16
- 230000024932 T cell mediated immunity Effects 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 230000001681 protective effect Effects 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 210000004988 splenocyte Anatomy 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000005951 type IV hypersensitivity Effects 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 239000011324 bead Substances 0.000 description 13
- 239000002054 inoculum Substances 0.000 description 13
- 210000003462 vein Anatomy 0.000 description 13
- 101710198693 Invasin Proteins 0.000 description 12
- 108010052285 Membrane Proteins Proteins 0.000 description 12
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 description 12
- 241000191940 Staphylococcus Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 231100000419 toxicity Toxicity 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 11
- 239000012981 Hank's balanced salt solution Substances 0.000 description 11
- 102000018697 Membrane Proteins Human genes 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000003656 tris buffered saline Substances 0.000 description 10
- 102100037642 Elongation factor G, mitochondrial Human genes 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 231100000518 lethal Toxicity 0.000 description 9
- 230000001665 lethal effect Effects 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 108091061303 ALS family Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 230000004709 cell invasion Effects 0.000 description 8
- 238000012937 correction Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000001325 log-rank test Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 229940037003 alum Drugs 0.000 description 7
- 229940121375 antifungal agent Drugs 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000001000 micrograph Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 210000005253 yeast cell Anatomy 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 210000000447 Th1 cell Anatomy 0.000 description 6
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000003176 fibrotic effect Effects 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 244000309462 non-albicans Candida Species 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 101150100395 ALS1 gene Proteins 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241001496375 Iris albicans Species 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 5
- -1 analogs Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000001032 anti-candidal effect Effects 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002983 circular dichroism Methods 0.000 description 5
- 238000001142 circular dichroism spectrum Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000012202 endocytosis Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004727 humoral immunity Effects 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000010959 steel Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- 238000001261 affinity purification Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000000556 factor analysis Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001024 immunotherapeutic effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229920000057 Mannan Polymers 0.000 description 3
- 229920001410 Microfiber Polymers 0.000 description 3
- 206010065764 Mucosal infection Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 101150085390 RPM1 gene Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 101150001810 TEAD1 gene Proteins 0.000 description 3
- 101150074253 TEF1 gene Proteins 0.000 description 3
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 208000037815 bloodstream infection Diseases 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 3
- 239000003658 microfiber Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000000329 molecular dynamics simulation Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 230000007923 virulence factor Effects 0.000 description 3
- 239000000304 virulence factor Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 101150094738 ALS3 gene Proteins 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102100026045 Exosome complex component RRP42 Human genes 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 101150057219 HWP1 gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000915428 Homo sapiens Death domain-associated protein 6 Proteins 0.000 description 2
- 101001055992 Homo sapiens Exosome complex component RRP42 Proteins 0.000 description 2
- 101000599816 Homo sapiens Probable E3 ubiquitin-protein ligase IRF2BPL Proteins 0.000 description 2
- 101001087372 Homo sapiens Securin Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 238000003231 Lowry assay Methods 0.000 description 2
- 238000009013 Lowry's assay Methods 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100027287 Serpin H1 Human genes 0.000 description 2
- 108050008290 Serpin H1 Proteins 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 101150050575 URA3 gene Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 102000021124 collagen binding proteins Human genes 0.000 description 2
- 108091011142 collagen binding proteins Proteins 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005421 electrostatic potential Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108091006082 receptor inhibitors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- MKPCNMXYTMQZBE-UHFFFAOYSA-N 7h-purin-6-amine;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.NC1=NC=NC2=C1NC=N2.NC1=NC=NC2=C1NC=N2 MKPCNMXYTMQZBE-UHFFFAOYSA-N 0.000 description 1
- 101150118692 ALS5 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 101710204899 Alpha-agglutinin Proteins 0.000 description 1
- 201000008162 B cell deficiency Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 241001416152 Bos frontalis Species 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 108700020335 Candida albicans ALS1 Proteins 0.000 description 1
- 101100055410 Candida albicans ALS1 gene Proteins 0.000 description 1
- 241000675278 Candida albicans SC5314 Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101100137154 Danio rerio pou5f1 gene Proteins 0.000 description 1
- 241000160765 Erebia ligea Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 101001047819 Homo sapiens Heparanase Proteins 0.000 description 1
- 101000823931 Homo sapiens Spatacsin Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 101710092857 Integrator complex subunit 1 Proteins 0.000 description 1
- 102100024061 Integrator complex subunit 1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 101100321764 Mesorhizobium japonicum (strain LMG 29417 / CECT 9101 / MAFF 303099) padh1 gene Proteins 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100109406 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aga-1 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 240000004604 Ptychosperma elegans Species 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100032136 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PYC2 gene Proteins 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102100022077 Spatacsin Human genes 0.000 description 1
- 201000001322 T cell deficiency Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000006271 Vitex glabrata Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000145 adjuvantlike effect Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 201000002773 amyotrophic lateral sclerosis type 13 Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000005102 attenuated total reflection Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000017773 candidemia Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000023578 negative regulation of cell adhesion Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000004763 spore germination Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GZXOHHPYODFEGO-UHFFFAOYSA-N triglycine sulfate Chemical class NCC(O)=O.NCC(O)=O.NCC(O)=O.OS(O)(=O)=O GZXOHHPYODFEGO-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/123,873 US20060083750A1 (en) | 1999-11-19 | 2005-05-05 | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| PCT/US2006/017482 WO2006121895A2 (en) | 2005-05-05 | 2006-05-04 | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540453A true JP2008540453A (ja) | 2008-11-20 |
| JP2008540453A5 JP2008540453A5 (enExample) | 2009-05-14 |
Family
ID=37397150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510281A Pending JP2008540453A (ja) | 2005-05-05 | 2006-05-04 | 播種性カンジダ症および他の感染性因子に対してワクチン接種するための薬学的組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060083750A1 (enExample) |
| EP (1) | EP1883421A4 (enExample) |
| JP (1) | JP2008540453A (enExample) |
| AU (1) | AU2006244401B2 (enExample) |
| CA (1) | CA2607176A1 (enExample) |
| WO (1) | WO2006121895A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009524601A (ja) * | 2006-01-06 | 2009-07-02 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法 |
| JP2012532114A (ja) * | 2009-07-03 | 2012-12-13 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | カンジダに対する能動免疫及び受動免疫の標的としてのｈｙｒ１ |
| US10130691B2 (en) | 2013-03-15 | 2018-11-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Compositions and methods for treating fungal and bacterial pathogens |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2871081A1 (en) * | 2011-04-21 | 2012-10-26 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Peptide and conjugate vaccines for fungal infections |
| CN103998056B (zh) * | 2011-07-22 | 2017-09-12 | 诺瓦蒂格姆疗法有限公司 | 用于接种抗金黄色葡萄球菌疫苗的方法和组合物 |
| CN108883167A (zh) | 2016-03-09 | 2018-11-23 | 加州大学洛杉矶分校港口医学中心生物医学研究所 | 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124134A1 (en) * | 1999-11-19 | 2003-07-03 | Harbor-Ucla Research And Education Institute | Pharmaceutical compositions and methods to vaccinate against candidiasis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622939A (en) * | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
| US5668263A (en) * | 1994-12-16 | 1997-09-16 | Smithkline Beecham Corporation | Conserved yeast nucleic acid sequences |
| US5858378A (en) * | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US6747137B1 (en) * | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US7067138B1 (en) * | 1999-11-19 | 2006-06-27 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis |
| US20070077256A1 (en) * | 1999-11-19 | 2007-04-05 | Los Angeles Biomedical Research Institute | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| CA2325774C (en) * | 1999-12-10 | 2011-02-08 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food | Coniothyrium minitans .beta.-(1,3) exoglucanase gene cbeg1 |
| US7241613B1 (en) * | 2002-06-05 | 2007-07-10 | Oscient Pharmaceuticals Corporation | Identification of Candida cell surface proteins and their uses |
| UA109105C2 (uk) * | 2006-04-17 | 2015-07-27 | Молекула нуклеїнової кислоти, що кодує істотно нетоксичний мутеїн альфа-токсину clostridium perfringens, та істотно нетоксичний мутеїн альфа-токсину clostridium perfringens |
-
2005
- 2005-05-05 US US11/123,873 patent/US20060083750A1/en not_active Abandoned
-
2006
- 2006-05-04 EP EP06752341A patent/EP1883421A4/en not_active Withdrawn
- 2006-05-04 WO PCT/US2006/017482 patent/WO2006121895A2/en not_active Ceased
- 2006-05-04 AU AU2006244401A patent/AU2006244401B2/en not_active Ceased
- 2006-05-04 CA CA002607176A patent/CA2607176A1/en not_active Abandoned
- 2006-05-04 JP JP2008510281A patent/JP2008540453A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124134A1 (en) * | 1999-11-19 | 2003-07-03 | Harbor-Ucla Research And Education Institute | Pharmaceutical compositions and methods to vaccinate against candidiasis |
Non-Patent Citations (2)
| Title |
|---|
| JPN6011065264; ＭＩＣＲＯＢＩＯＬＯＧＹ ＡＮＤ ＩＭＭＵＮＯＬＯＧＹ Ｖｏｌ．４４，Ｎｏ．５, 2000, ｐ．３８１-３８４ * |
| JPN6011065265; ＴＨＥ ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＬＯＧＩＣＡＬ ＣＨＥＭＩＳＴＲＹ Ｖｏｌ．２７９，Ｎｏ．２９, 2004, ｐ．３０４８０-３０４８９ * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10300120B2 (en) | 2002-09-13 | 2019-05-28 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| JP2009524601A (ja) * | 2006-01-06 | 2009-07-02 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法 |
| JP2012532114A (ja) * | 2009-07-03 | 2012-12-13 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | カンジダに対する能動免疫及び受動免疫の標的としてのｈｙｒ１ |
| JP2015120722A (ja) * | 2009-07-03 | 2015-07-02 | ロサンゼルス バイオメディカル リサーチ インスティテュート アットハーバー− ユーシーエルエー メディカル センター | カンジダに対する能動免疫及び受動免疫の標的としてのｈｙｒ１ |
| US10130691B2 (en) | 2013-03-15 | 2018-11-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Compositions and methods for treating fungal and bacterial pathogens |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006121895A2 (en) | 2006-11-16 |
| AU2006244401A1 (en) | 2006-11-16 |
| EP1883421A2 (en) | 2008-02-06 |
| US20060083750A1 (en) | 2006-04-20 |
| AU2006244401A8 (en) | 2006-11-16 |
| EP1883421A4 (en) | 2009-12-16 |
| CA2607176A1 (en) | 2006-11-16 |
| WO2006121895A3 (en) | 2007-06-07 |
| AU2006244401B2 (en) | 2012-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5775044B2 (ja) | 播種性カンジダ症および他の感染性因子に対するワクチン接種をするための医薬組成物および方法 | |
| Sui et al. | The vaccines and antibodies associated with Als3p for treatment of Candida albicans infections | |
| Wang et al. | Vaccines in the treatment of invasive candidiasis | |
| EP2448959B1 (en) | Hyr1 as a target for active and passive immunization against candida | |
| Mochon et al. | Prospects of vaccines for medically important fungi Is a vaccine needed against Candida albicans? | |
| JP2008540453A (ja) | 播種性カンジダ症および他の感染性因子に対してワクチン接種するための薬学的組成物および方法 | |
| AU2013203750A1 (en) | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents | |
| AU2012216520A1 (en) | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents | |
| Chandley et al. | Role of Vaccines and Monoclonal Antibodies in Systemic Candidiasis: Past and Future Approaches | |
| Mochon et al. | Prospects of vaccines for medically important fungi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090324 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120309 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120316 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120329 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120405 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120511 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120518 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120612 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121026 |